Siwa Therapeutics
  • Home
  • Leadership
  • Science
  • Data
  • Media
    • News
    • Videos
  • Partners
  • Contact

Month: January 2018

Home / 2018 / January
09Jan 2018 by Andrew Premovich

Third Annual Healthspan Extension Policy and Regulation Workshop

Events
- Upcoming
Read More

Recent Posts

  • Listen to our founder and CEO, Lewis Gruber discuss SIWA and 318H!
  • In The News: Supertrends
  • Press Release: SIWA Therapeutics Grows Leadership Team with Appointment of Gabriela Rossi, Ph.D.
  • In The News: Startup.info Interview
  • In The News: BIOSPACE

Archives

  • April 2021
  • October 2020
  • September 2020
  • June 2020
  • May 2020
  • March 2020
  • February 2020
  • September 2019
  • March 2019
  • April 2018
  • January 2018
  • June 2017
  • May 2017
  • October 2016

Categories

  • Events
  • In The News
  • News
  • Press Releases
  • Uncategorized

About Us

SIWA’s 318H monoclonal antibody targets a biomarker on cancer cells, senescent cells, and microbially-infected cells. Our initial focus is on gastrointestinal and related diseases that are eligible for FDA Fast-tracking. We expect to file our first IND in late 2021 jointly with a major institution in pancreatic cancer/cachexia. ***

Recent News

  • Listen to our founder and CEO, Lewis Gruber discuss SIWA and 318H!
  • In The News: Supertrends
  • Press Release: SIWA Therapeutics Grows Leadership Team with Appointment of Gabriela Rossi, Ph.D.

JOIN OUR MAILING LIST

Navigation

  • Home
  • Leadership
  • Science
  • Data
  • Media
    • News
    • Videos
  • Partners
  • Contact